Severe preeclampsia is characterized by increased placental expression of galectin-1

Nandor Gabor Than, Offer Erez, Derek E. Wildman, Adi L. Tarca, Samuel S. Edwin, Asad Abbas, John Hotra, Juan Pedro Kusanovic, Francesca Gotsch, Sonia S. Hassan, Jimmy Espinoza, Z. Papp, Roberto Romero

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective. Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character of inflammatory responses toward the Th2 type. Galectin-1 is expressed in immune privileged sites, it can facilitate immune tolerance and tumor immune escape, and it has been successfully used for the suppression of experimental autoimmune diseases as well as graft-versus-host disease in murine models. We propose that an abnormal immune response in some pregnancy complications may be associated with changes in placental expression of galectin-1. To test this hypothesis, we studied placental galectin-1 mRNA and protein expression and localization in women with preeclampsia (PE) and in those who delivered a small-for-gestational age (SGA) neonate. Study design. This cross-sectional study included pregnant women matched for gestational age at delivery in the following groups: (1) severe PE (n = 10), (2) severe PE complicated with SGA (n = 10), (3) SGA without PE (n = 10), and (4) controls (n = 10). Galectin-1 mRNA and protein were localized in placentas by in situ hybridization and immunofluorescence microscopy. Galectin-1 mRNA expression was determined by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR), and galectin-1 protein content by Western blot. Non-parametric statistics were used for analysis. Results. (1) In normal term placentas, galectin-1 mRNA or immunofluorescence signals were detected in the trophoblasts, villous stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels, and the villous stroma. (2) Placental galectin-1 mRNA expression was significantly higher in severe PE (with or without SGA) than in controls (1.47-fold, p = 0.004; 1.44-fold, p = 0.003, respectively) and in SGA (1.68-fold, p = 0.001; 1.64-fold, p = 0.001, respectively). (3) Trophoblasts in placentas of patients with severe PE had the most intense galectin-1 immunostaining. Conclusions. (1) We report for the first time the placental expression and localization of galectin-1 mRNA and demonstrate that the protein is abundantly present in third trimester human placentas. (2) Placental galectin-1 expression is higher in severe PE than in normal pregnancy regardless of the presence of SGA. (3) However, it is not altered in SGA without PE. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a fetal response to an exaggerated systemic maternal inflammation; thus, galectin-1 may be implicated in maternal-fetal immune tolerance in humans.

Original languageEnglish
Pages (from-to)429-442
Number of pages14
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume21
Issue number7
DOIs
Publication statusPublished - 2008

Fingerprint

Galectin 1
Pre-Eclampsia
Gestational Age
Placenta
Messenger RNA
Immune Tolerance
Trophoblasts
Proteins
Mothers
Tumor Escape
Pregnancy Complications
Third Pregnancy Trimester
Graft vs Host Disease
Stromal Cells
Nonparametric Statistics

Keywords

  • Glycocode
  • Inflammation
  • Lectin
  • Pregnancy
  • Semi-allograft
  • Tolerance
  • Trophoblast

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology

Cite this

Than, N. G., Erez, O., Wildman, D. E., Tarca, A. L., Edwin, S. S., Abbas, A., ... Romero, R. (2008). Severe preeclampsia is characterized by increased placental expression of galectin-1. Journal of Maternal-Fetal and Neonatal Medicine, 21(7), 429-442. https://doi.org/10.1080/14767050802041961

Severe preeclampsia is characterized by increased placental expression of galectin-1. / Than, Nandor Gabor; Erez, Offer; Wildman, Derek E.; Tarca, Adi L.; Edwin, Samuel S.; Abbas, Asad; Hotra, John; Kusanovic, Juan Pedro; Gotsch, Francesca; Hassan, Sonia S.; Espinoza, Jimmy; Papp, Z.; Romero, Roberto.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 21, No. 7, 2008, p. 429-442.

Research output: Contribution to journalArticle

Than, NG, Erez, O, Wildman, DE, Tarca, AL, Edwin, SS, Abbas, A, Hotra, J, Kusanovic, JP, Gotsch, F, Hassan, SS, Espinoza, J, Papp, Z & Romero, R 2008, 'Severe preeclampsia is characterized by increased placental expression of galectin-1', Journal of Maternal-Fetal and Neonatal Medicine, vol. 21, no. 7, pp. 429-442. https://doi.org/10.1080/14767050802041961
Than, Nandor Gabor ; Erez, Offer ; Wildman, Derek E. ; Tarca, Adi L. ; Edwin, Samuel S. ; Abbas, Asad ; Hotra, John ; Kusanovic, Juan Pedro ; Gotsch, Francesca ; Hassan, Sonia S. ; Espinoza, Jimmy ; Papp, Z. ; Romero, Roberto. / Severe preeclampsia is characterized by increased placental expression of galectin-1. In: Journal of Maternal-Fetal and Neonatal Medicine. 2008 ; Vol. 21, No. 7. pp. 429-442.
@article{7dea2ecc3cd34a7fa3e603da075fc566,
title = "Severe preeclampsia is characterized by increased placental expression of galectin-1",
abstract = "Objective. Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character of inflammatory responses toward the Th2 type. Galectin-1 is expressed in immune privileged sites, it can facilitate immune tolerance and tumor immune escape, and it has been successfully used for the suppression of experimental autoimmune diseases as well as graft-versus-host disease in murine models. We propose that an abnormal immune response in some pregnancy complications may be associated with changes in placental expression of galectin-1. To test this hypothesis, we studied placental galectin-1 mRNA and protein expression and localization in women with preeclampsia (PE) and in those who delivered a small-for-gestational age (SGA) neonate. Study design. This cross-sectional study included pregnant women matched for gestational age at delivery in the following groups: (1) severe PE (n = 10), (2) severe PE complicated with SGA (n = 10), (3) SGA without PE (n = 10), and (4) controls (n = 10). Galectin-1 mRNA and protein were localized in placentas by in situ hybridization and immunofluorescence microscopy. Galectin-1 mRNA expression was determined by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR), and galectin-1 protein content by Western blot. Non-parametric statistics were used for analysis. Results. (1) In normal term placentas, galectin-1 mRNA or immunofluorescence signals were detected in the trophoblasts, villous stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels, and the villous stroma. (2) Placental galectin-1 mRNA expression was significantly higher in severe PE (with or without SGA) than in controls (1.47-fold, p = 0.004; 1.44-fold, p = 0.003, respectively) and in SGA (1.68-fold, p = 0.001; 1.64-fold, p = 0.001, respectively). (3) Trophoblasts in placentas of patients with severe PE had the most intense galectin-1 immunostaining. Conclusions. (1) We report for the first time the placental expression and localization of galectin-1 mRNA and demonstrate that the protein is abundantly present in third trimester human placentas. (2) Placental galectin-1 expression is higher in severe PE than in normal pregnancy regardless of the presence of SGA. (3) However, it is not altered in SGA without PE. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a fetal response to an exaggerated systemic maternal inflammation; thus, galectin-1 may be implicated in maternal-fetal immune tolerance in humans.",
keywords = "Glycocode, Inflammation, Lectin, Pregnancy, Semi-allograft, Tolerance, Trophoblast",
author = "Than, {Nandor Gabor} and Offer Erez and Wildman, {Derek E.} and Tarca, {Adi L.} and Edwin, {Samuel S.} and Asad Abbas and John Hotra and Kusanovic, {Juan Pedro} and Francesca Gotsch and Hassan, {Sonia S.} and Jimmy Espinoza and Z. Papp and Roberto Romero",
year = "2008",
doi = "10.1080/14767050802041961",
language = "English",
volume = "21",
pages = "429--442",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Severe preeclampsia is characterized by increased placental expression of galectin-1

AU - Than, Nandor Gabor

AU - Erez, Offer

AU - Wildman, Derek E.

AU - Tarca, Adi L.

AU - Edwin, Samuel S.

AU - Abbas, Asad

AU - Hotra, John

AU - Kusanovic, Juan Pedro

AU - Gotsch, Francesca

AU - Hassan, Sonia S.

AU - Espinoza, Jimmy

AU - Papp, Z.

AU - Romero, Roberto

PY - 2008

Y1 - 2008

N2 - Objective. Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character of inflammatory responses toward the Th2 type. Galectin-1 is expressed in immune privileged sites, it can facilitate immune tolerance and tumor immune escape, and it has been successfully used for the suppression of experimental autoimmune diseases as well as graft-versus-host disease in murine models. We propose that an abnormal immune response in some pregnancy complications may be associated with changes in placental expression of galectin-1. To test this hypothesis, we studied placental galectin-1 mRNA and protein expression and localization in women with preeclampsia (PE) and in those who delivered a small-for-gestational age (SGA) neonate. Study design. This cross-sectional study included pregnant women matched for gestational age at delivery in the following groups: (1) severe PE (n = 10), (2) severe PE complicated with SGA (n = 10), (3) SGA without PE (n = 10), and (4) controls (n = 10). Galectin-1 mRNA and protein were localized in placentas by in situ hybridization and immunofluorescence microscopy. Galectin-1 mRNA expression was determined by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR), and galectin-1 protein content by Western blot. Non-parametric statistics were used for analysis. Results. (1) In normal term placentas, galectin-1 mRNA or immunofluorescence signals were detected in the trophoblasts, villous stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels, and the villous stroma. (2) Placental galectin-1 mRNA expression was significantly higher in severe PE (with or without SGA) than in controls (1.47-fold, p = 0.004; 1.44-fold, p = 0.003, respectively) and in SGA (1.68-fold, p = 0.001; 1.64-fold, p = 0.001, respectively). (3) Trophoblasts in placentas of patients with severe PE had the most intense galectin-1 immunostaining. Conclusions. (1) We report for the first time the placental expression and localization of galectin-1 mRNA and demonstrate that the protein is abundantly present in third trimester human placentas. (2) Placental galectin-1 expression is higher in severe PE than in normal pregnancy regardless of the presence of SGA. (3) However, it is not altered in SGA without PE. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a fetal response to an exaggerated systemic maternal inflammation; thus, galectin-1 may be implicated in maternal-fetal immune tolerance in humans.

AB - Objective. Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character of inflammatory responses toward the Th2 type. Galectin-1 is expressed in immune privileged sites, it can facilitate immune tolerance and tumor immune escape, and it has been successfully used for the suppression of experimental autoimmune diseases as well as graft-versus-host disease in murine models. We propose that an abnormal immune response in some pregnancy complications may be associated with changes in placental expression of galectin-1. To test this hypothesis, we studied placental galectin-1 mRNA and protein expression and localization in women with preeclampsia (PE) and in those who delivered a small-for-gestational age (SGA) neonate. Study design. This cross-sectional study included pregnant women matched for gestational age at delivery in the following groups: (1) severe PE (n = 10), (2) severe PE complicated with SGA (n = 10), (3) SGA without PE (n = 10), and (4) controls (n = 10). Galectin-1 mRNA and protein were localized in placentas by in situ hybridization and immunofluorescence microscopy. Galectin-1 mRNA expression was determined by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR), and galectin-1 protein content by Western blot. Non-parametric statistics were used for analysis. Results. (1) In normal term placentas, galectin-1 mRNA or immunofluorescence signals were detected in the trophoblasts, villous stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels, and the villous stroma. (2) Placental galectin-1 mRNA expression was significantly higher in severe PE (with or without SGA) than in controls (1.47-fold, p = 0.004; 1.44-fold, p = 0.003, respectively) and in SGA (1.68-fold, p = 0.001; 1.64-fold, p = 0.001, respectively). (3) Trophoblasts in placentas of patients with severe PE had the most intense galectin-1 immunostaining. Conclusions. (1) We report for the first time the placental expression and localization of galectin-1 mRNA and demonstrate that the protein is abundantly present in third trimester human placentas. (2) Placental galectin-1 expression is higher in severe PE than in normal pregnancy regardless of the presence of SGA. (3) However, it is not altered in SGA without PE. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a fetal response to an exaggerated systemic maternal inflammation; thus, galectin-1 may be implicated in maternal-fetal immune tolerance in humans.

KW - Glycocode

KW - Inflammation

KW - Lectin

KW - Pregnancy

KW - Semi-allograft

KW - Tolerance

KW - Trophoblast

UR - http://www.scopus.com/inward/record.url?scp=47349088661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47349088661&partnerID=8YFLogxK

U2 - 10.1080/14767050802041961

DO - 10.1080/14767050802041961

M3 - Article

C2 - 18570123

AN - SCOPUS:47349088661

VL - 21

SP - 429

EP - 442

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 7

ER -